Venrock Healthcare Entities Acquire 6.2% Stake in Relmada Therapeutics, Inc.

On June 9, 2026, a group of reporting persons led by Venrock Healthcare Capital Partners III, L.P. filed a Schedule 13G regarding their holdings in Relmada Therapeutics, Inc. (RLMD). The filing reveals that the group collectively owns 6,508,433 shares of common stock, representing a 6.2% ownership stake in the company. This position was established through holdings across several entities, including Venrock Healthcare Capital Partners III, L.P. (1,693,738 shares), VHCP Co-Investment Holdings III, LLC (169,427 shares), and Venrock Healthcare Capital Partners EG, L.P. (4,645,268 shares). The reporting persons include VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, who serve as voting members and managers of the respective investment vehicles. The percentage ownership is based on 104,890,223 shares outstanding as of May 11, 2026. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.